View ValuationOscotec 将来の成長Future 基準チェック /66Oscotec利益と収益がそれぞれ年間34.6%と28.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に38.4% 34.6%なると予測されています。主要情報34.6%収益成長率34.62%EPS成長率Pharmaceuticals 収益成長20.6%収益成長率28.4%将来の株主資本利益率38.40%アナリストカバレッジLow最終更新日14 Apr 2026今後の成長に関する最新情報Major Estimate Revision • Apr 15Consensus EPS estimates increase by 32%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from ₩639 to ₩841. Revenue forecast unchanged at ₩84.0m. Net income forecast to shrink 39% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target of ₩75,000 unchanged from last update. Share price rose 17% to ₩57,200 over the past week.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩41,000, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 61% over the past three years.Major Estimate Revision • Apr 15Consensus EPS estimates increase by 32%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from ₩639 to ₩841. Revenue forecast unchanged at ₩84.0m. Net income forecast to shrink 39% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target of ₩75,000 unchanged from last update. Share price rose 17% to ₩57,200 over the past week.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩55,200, the stock trades at a forward P/E ratio of 86x. Average forward P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past three years.分析記事 • Mar 30Oscotec's (KOSDAQ:039200) Earnings Are Weaker Than They SeemInvestors were disappointed with Oscotec Inc.'s ( KOSDAQ:039200 ) earnings, despite the strong profit numbers. Our...New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 1.0% per year for the foreseeable future. High level of non-cash earnings (65% accrual ratio).お知らせ • Mar 13Oscotec Inc., Annual General Meeting, Mar 30, 2026Oscotec Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaReported Earnings • Nov 14Third quarter 2025 earnings released: ₩13.00 loss per share (vs ₩442 profit in 3Q 2024)Third quarter 2025 results: ₩13.00 loss per share (down from ₩442 profit in 3Q 2024). Revenue: ₩8.95b (down 69% from 3Q 2024). Net loss: ₩489.3m (down 103% from profit in 3Q 2024). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.分析記事 • Sep 19Oscotec Inc.'s (KOSDAQ:039200) 32% Jump Shows Its Popularity With InvestorsOscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 32% gain in the last month alone...分析記事 • Aug 13Despite Lacking Profits Oscotec (KOSDAQ:039200) Seems To Be On Top Of Its DebtKOSDAQ:A039200 1 Year Share Price vs Fair Value Explore Oscotec's Fair Values from the Community and select yours...分析記事 • Jul 03Oscotec Inc. (KOSDAQ:039200) Not Flying Under The RadarWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...分析記事 • Mar 26Oscotec Inc. (KOSDAQ:039200) Looks Just Right With A 26% Price JumpOscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 26% gain in the last month alone...お知らせ • Feb 27Oscotec Inc., Annual General Meeting, Mar 27, 2025Oscotec Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Feb 16Rock star Growth Puts Oscotec (KOSDAQ:039200) In A Position To Use DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Nov 20With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay ForThe Oscotec Inc. ( KOSDAQ:039200 ) share price has fared very poorly over the last month, falling by a substantial 38...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).分析記事 • Aug 07Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 26Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 21Full year 2023 earnings released: ₩635 loss per share (vs ₩763 loss in FY 2022)Full year 2023 results: ₩635 loss per share (improved from ₩763 loss in FY 2022). Net loss: ₩24.3b (flat on FY 2022). Revenue is forecast to grow 94% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Mar 07Now 23% undervaluedOver the last 90 days, the stock has risen 19% to ₩24,050. The fair value is estimated to be ₩31,314, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Earnings per share has declined by 16%.お知らせ • Feb 23Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's DiseaseOscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease. Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y01 is uniquely designed to target tau protein acetylated at lysine-280 (acK280), inhibiting aggregation and propagation of toxic tau and thus may slow the course of the disease. This phase 1a/1b study in the U.S. is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ADEL-Y01 in 40 healthy volunteers as well as in 33 participants with Mild Cognitive Impairment due to Alzheimer's disease or mild Alzheimer's disease. The preclinical results of ADEL-Y01 in animal models were published last year, demonstrating improvement in memory impairment, behavioral deficits through the inhibition of Tau seeding and propagation.Buying Opportunity • Dec 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩28,990, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Earnings per share has declined by 16%.Buying Opportunity • Oct 18Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be ₩27,229, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Earnings per share has declined by 23%.お知らせ • Sep 15Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's DiseaseOscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that recognizes and binds to tau protein acetylated at lysine-280 (acK280) thus inhibiting aggregation and propagation of tau seeds and enhancing microglial tau clearance. Administration of ADEL-Y01 has ameliorated memory impairment, behavioral deficits, and tau pathology in preclinical models, which was published early this year ("Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models" in The Journal of Clinical Investigation) This phase 1a/1b study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ADEL-Y01 in healthy volunteers as well as in participants with Mild Cognitive Impairment due to Alzheimer's disease or mild Alzheimer's disease.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: ₩866 loss per share (down from ₩145 loss in FY 2020). Revenue: ₩3.90b (down 91% from FY 2020). Net loss: ₩26.3b (loss widened ₩21.9b from FY 2020). Revenue missed analyst estimates by 7.2%. Over the next year, revenue is forecast to grow 14% compared to a 1.5% decline forecast for the pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Reported Earnings • Mar 11Full year 2020 earnings released: ₩155 loss per share (vs ₩801 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩43.5b (up ₩39.1b from FY 2019). Net loss: ₩4.36b (loss narrowed 81% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • Mar 03Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer DrugOscotec Inc. and Beactica Therapeutics AB announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization. Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme. Beactica is eligible to receive up to EUR 149 million in potential preclinical, clinical and regulatory milestones, including an upfront and equity payment from Oscotec upon signing of the agreement. Furthermore, Beactica is eligible to receive double-digit royalties on commercial sales of the products resulting from the partnership. Beactica is also entitled to revenue shares from any related future licensing activities by Oscotec. Full financial details remain undisclosed.お知らせ • Feb 25Oscotec Inc., Annual General Meeting, Mar 25, 2021Oscotec Inc., Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time.分析記事 • Feb 23Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?Every investor in Oscotec Inc. ( KOSDAQ:039200 ) should be aware of the most powerful shareholder groups. Insiders...Is New 90 Day High Low • Feb 17New 90-day low: ₩36,100The company is down 37% from its price of ₩57,100 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: ₩40,350The company is down 2.0% from its price of ₩41,150 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.分析記事 • Jan 19If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% ReturnsIt might be of some concern to shareholders to see the Oscotec Inc. ( KOSDAQ:039200 ) share price down 27% in the last...分析記事 • Dec 15Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Dec 07New 90-day high: ₩69,500The company is up 78% from its price of ₩39,050 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 04New 90-day high: ₩51,400The company is up 70% from its price of ₩30,150 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 07New 90-day high: ₩49,700The company is up 112% from its price of ₩23,450 on 09 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 18New 90-day high: ₩44,250The company is up 54% from its price of ₩28,750 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.業績と収益の成長予測KOSDAQ:A039200 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028238,000154,000153,000153,000112/31/2027144,00063,500120,00050,500212/31/202684,00032,000101,000102,000112/31/202599,83952,3437,5238,302N/A9/30/202523,235-13,139-1,454-489N/A6/30/202543,3454,2544341,449N/A3/31/202534,8823854,5025,037N/A12/31/202434,008877-26,726-26,034N/A9/30/202431,977-4,882-20,004-19,544N/A6/30/20244,618-26,305-22,855-22,255N/A3/31/20244,864-24,445-23,730-22,965N/A12/31/20234,951-24,280-22,629-22,048N/A9/30/20236,019-18,215-26,720-25,836N/A6/30/20235,436-20,166-24,810-23,692N/A3/31/20235,180-22,047-26,695-25,449N/A12/31/20225,062-24,430-27,670-26,421N/A9/30/20224,848-25,213-31,904-28,735N/A6/30/20224,588-25,062-36,352-28,562N/A3/31/20224,039-24,371-10,660-3,141N/A12/31/20213,903-26,263-16,280-8,762N/A9/30/202128,955-17,734-18,453-11,618N/A6/30/202128,885-18,3022302,206N/A3/31/202143,415-7,467-26,451-23,225N/A12/31/202043,471-4,357-23,104-17,881N/A9/30/202018,182-15,501-16,501-12,552N/A6/30/202018,634-12,346-28,208-24,002N/A3/31/20204,221-24,584-14,835-8,161N/A12/31/20194,369-22,601-4,64027N/A9/30/201918,885-4,909N/A5,227N/A6/30/201918,782-5,393N/A5,107N/A3/31/201918,657-258N/A-1,877N/A12/31/201818,7033,371N/A-5,078N/A9/30/20183,917-8,415N/A-6,523N/A6/30/20183,809-5,537N/A-3,880N/A3/31/20183,721-5,361N/A-3,770N/A12/31/20173,908-5,857N/A-3,689N/A9/30/20174,600-7,465N/A-11,506N/A6/30/20174,343-7,013N/A-4,975N/A3/31/20173,968-9,485N/A-8,261N/A12/31/20163,554-8,851N/A-8,209N/A9/30/20166,816-5,256N/A1,280N/A6/30/201611,714-2,985N/A-3,061N/A3/31/201614,895259N/A-360N/A12/31/201518,336395N/A645N/A9/30/201517,441-1,063N/A126N/A6/30/201516,514-2,615N/A-1,071N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A039200の予測収益成長率 (年間34.6% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A039200の収益 ( 34.6% ) はKR市場 ( 31.2% ) よりも速いペースで成長すると予測されています。高成長収益: A039200の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: A039200の収益 ( 28.4% ) KR市場 ( 15.5% ) よりも速いペースで成長すると予測されています。高い収益成長: A039200の収益 ( 28.4% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A039200の 自己資本利益率 は、3年後には高くなると予測されています ( 38.4 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:48終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oscotec Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Haesoon KwonEugene Investment & Securities Co Ltd.Sangsoo KimGoldman SachsWan KuiM Securities2 その他のアナリストを表示
Major Estimate Revision • Apr 15Consensus EPS estimates increase by 32%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from ₩639 to ₩841. Revenue forecast unchanged at ₩84.0m. Net income forecast to shrink 39% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target of ₩75,000 unchanged from last update. Share price rose 17% to ₩57,200 over the past week.
Valuation Update With 7 Day Price Move • May 19Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩41,000, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 61% over the past three years.
Major Estimate Revision • Apr 15Consensus EPS estimates increase by 32%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from ₩639 to ₩841. Revenue forecast unchanged at ₩84.0m. Net income forecast to shrink 39% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target of ₩75,000 unchanged from last update. Share price rose 17% to ₩57,200 over the past week.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩55,200, the stock trades at a forward P/E ratio of 86x. Average forward P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past three years.
分析記事 • Mar 30Oscotec's (KOSDAQ:039200) Earnings Are Weaker Than They SeemInvestors were disappointed with Oscotec Inc.'s ( KOSDAQ:039200 ) earnings, despite the strong profit numbers. Our...
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 1.0% per year for the foreseeable future. High level of non-cash earnings (65% accrual ratio).
お知らせ • Mar 13Oscotec Inc., Annual General Meeting, Mar 30, 2026Oscotec Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
Reported Earnings • Nov 14Third quarter 2025 earnings released: ₩13.00 loss per share (vs ₩442 profit in 3Q 2024)Third quarter 2025 results: ₩13.00 loss per share (down from ₩442 profit in 3Q 2024). Revenue: ₩8.95b (down 69% from 3Q 2024). Net loss: ₩489.3m (down 103% from profit in 3Q 2024). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
分析記事 • Sep 19Oscotec Inc.'s (KOSDAQ:039200) 32% Jump Shows Its Popularity With InvestorsOscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 32% gain in the last month alone...
分析記事 • Aug 13Despite Lacking Profits Oscotec (KOSDAQ:039200) Seems To Be On Top Of Its DebtKOSDAQ:A039200 1 Year Share Price vs Fair Value Explore Oscotec's Fair Values from the Community and select yours...
分析記事 • Jul 03Oscotec Inc. (KOSDAQ:039200) Not Flying Under The RadarWhen you see that almost half of the companies in the Pharmaceuticals industry in Korea have price-to-sales ratios (or...
分析記事 • Mar 26Oscotec Inc. (KOSDAQ:039200) Looks Just Right With A 26% Price JumpOscotec Inc. ( KOSDAQ:039200 ) shares have continued their recent momentum with a 26% gain in the last month alone...
お知らせ • Feb 27Oscotec Inc., Annual General Meeting, Mar 27, 2025Oscotec Inc., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 700, daewangpangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Feb 16Rock star Growth Puts Oscotec (KOSDAQ:039200) In A Position To Use DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Nov 20With A 38% Price Drop For Oscotec Inc. (KOSDAQ:039200) You'll Still Get What You Pay ForThe Oscotec Inc. ( KOSDAQ:039200 ) share price has fared very poorly over the last month, falling by a substantial 38...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
分析記事 • Aug 07Oscotec (KOSDAQ:039200) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Apr 26Is Oscotec (KOSDAQ:039200) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 21Full year 2023 earnings released: ₩635 loss per share (vs ₩763 loss in FY 2022)Full year 2023 results: ₩635 loss per share (improved from ₩763 loss in FY 2022). Net loss: ₩24.3b (flat on FY 2022). Revenue is forecast to grow 94% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Mar 07Now 23% undervaluedOver the last 90 days, the stock has risen 19% to ₩24,050. The fair value is estimated to be ₩31,314, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Earnings per share has declined by 16%.
お知らせ • Feb 23Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's DiseaseOscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer's disease. Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y01 is uniquely designed to target tau protein acetylated at lysine-280 (acK280), inhibiting aggregation and propagation of toxic tau and thus may slow the course of the disease. This phase 1a/1b study in the U.S. is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ADEL-Y01 in 40 healthy volunteers as well as in 33 participants with Mild Cognitive Impairment due to Alzheimer's disease or mild Alzheimer's disease. The preclinical results of ADEL-Y01 in animal models were published last year, demonstrating improvement in memory impairment, behavioral deficits through the inhibition of Tau seeding and propagation.
Buying Opportunity • Dec 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩28,990, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 76% over the last 3 years. Earnings per share has declined by 16%.
Buying Opportunity • Oct 18Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 3.3%. The fair value is estimated to be ₩27,229, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Earnings per share has declined by 23%.
お知らせ • Sep 15Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's DiseaseOscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that recognizes and binds to tau protein acetylated at lysine-280 (acK280) thus inhibiting aggregation and propagation of tau seeds and enhancing microglial tau clearance. Administration of ADEL-Y01 has ameliorated memory impairment, behavioral deficits, and tau pathology in preclinical models, which was published early this year ("Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models" in The Journal of Clinical Investigation) This phase 1a/1b study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ADEL-Y01 in healthy volunteers as well as in participants with Mild Cognitive Impairment due to Alzheimer's disease or mild Alzheimer's disease.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: ₩866 loss per share (down from ₩145 loss in FY 2020). Revenue: ₩3.90b (down 91% from FY 2020). Net loss: ₩26.3b (loss widened ₩21.9b from FY 2020). Revenue missed analyst estimates by 7.2%. Over the next year, revenue is forecast to grow 14% compared to a 1.5% decline forecast for the pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 11Full year 2020 earnings released: ₩155 loss per share (vs ₩801 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩43.5b (up ₩39.1b from FY 2019). Net loss: ₩4.36b (loss narrowed 81% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • Mar 03Oscotec Inc. and Beactica Therapeutics AB Announces License and Collaboration Agreement to Develop New Cancer DrugOscotec Inc. and Beactica Therapeutics AB announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborate concerning research and early preclinical development of novel anti-cancer drug candidates arising out of Beactica's LSD1 programme. Oscotec may thereafter opt to take full responsibility for clinical development and commercialization. Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme. Beactica is eligible to receive up to EUR 149 million in potential preclinical, clinical and regulatory milestones, including an upfront and equity payment from Oscotec upon signing of the agreement. Furthermore, Beactica is eligible to receive double-digit royalties on commercial sales of the products resulting from the partnership. Beactica is also entitled to revenue shares from any related future licensing activities by Oscotec. Full financial details remain undisclosed.
お知らせ • Feb 25Oscotec Inc., Annual General Meeting, Mar 25, 2021Oscotec Inc., Annual General Meeting, Mar 25, 2021, at 09:00 Korea Standard Time.
分析記事 • Feb 23Is Oscotec Inc.'s (KOSDAQ:039200) Shareholder Ownership Skewed Towards Insiders?Every investor in Oscotec Inc. ( KOSDAQ:039200 ) should be aware of the most powerful shareholder groups. Insiders...
Is New 90 Day High Low • Feb 17New 90-day low: ₩36,100The company is down 37% from its price of ₩57,100 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: ₩40,350The company is down 2.0% from its price of ₩41,150 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
分析記事 • Jan 19If You Had Bought Oscotec (KOSDAQ:039200) Shares Five Years Ago You'd Have Earned 353% ReturnsIt might be of some concern to shareholders to see the Oscotec Inc. ( KOSDAQ:039200 ) share price down 27% in the last...
分析記事 • Dec 15Is Oscotec (KOSDAQ:039200) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Dec 07New 90-day high: ₩69,500The company is up 78% from its price of ₩39,050 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 04New 90-day high: ₩51,400The company is up 70% from its price of ₩30,150 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 07New 90-day high: ₩49,700The company is up 112% from its price of ₩23,450 on 09 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 18New 90-day high: ₩44,250The company is up 54% from its price of ₩28,750 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.